Detection of Infectious Bronchitis Virus Antigen from Experimentally Infected Chickens by Indirect Immunofluorescent Assay with Monoclonal Antibody

1990 ◽  
Vol 34 (2) ◽  
pp. 246 ◽  
Author(s):  
Kazuhiro Yagyu ◽  
Shuichi Ohta
Keyword(s):  
Monoclonal Antibody ◽  
Infectious Bronchitis Virus ◽  
Virus Antigen ◽  
Infectious Bronchitis ◽  
Immunofluorescent Assay ◽  
Indirect Immunofluorescent Assay ◽  
Indirect Immunofluorescent

scholarly journals Serological Survey of Ehrlichia canis and Anaplasma phagocytophilum in Dogs from Central Italy: An Update (2013–2017)

Pathogens ◽  
2019 ◽  
Vol 8 (1) ◽  
pp. 3 ◽  
Author(s):  
Valentina Virginia Ebani
Keyword(s):  
Anaplasma Phagocytophilum ◽  
Central Italy ◽  
Ehrlichia Canis ◽  
Serological Survey ◽  
Immunofluorescent Assay ◽  
Indirect Immunofluorescent Assay ◽  
Canine Population ◽  
Indirect Immunofluorescent

Ehrlichia canis and Anaplasma phagocytophilum are tick-borne bacteria of veterinary concern. Indirect immunofluorescent assay was carried out to detect antibodies against E. canis and A. phagocytophilum in 1026 owned dogs living in Central Italy during the period 2013–2017. One hundred and eighty-six (18.12%) dogs were positive for at least one pathogen and 14 (1.36%) for both agents. More in detail, 166 (16.18%) samples were positive for E. canis and 34 (3.31%) for A. phagocytophilum. No statistically significant differences in the seroprevalence values related to gender were detected, whereas the highest rate to E. canis occurred in animals aged more than 10 years. Mean seroprevalence values for both E. canis and A. phagocytophilum detected in 2014 and 2015 were statistically higher with respect to other years. Even though dogs’ owners are informed about the risk of pet infections by tick-borne pathogens and prophylaxis against ticks is often executed, E. canis and A. phagocytophilum are still present and infect the canine population in Central Italy.

scholarly journals Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France

2020 ◽  
Author(s):  
S. Edouard ◽  
P. Colson ◽  
C. Melenotte ◽  
F. De Pinto ◽  
L. Thomas ◽  
...  
Keyword(s):  
Therapeutic Option ◽  
Serum Samples ◽  
Positive Serology ◽  
Immunofluorescent Assay ◽  
Indirect Immunofluorescent Assay ◽  
Serological Status ◽  
Favourable Evolution ◽  
The Individual ◽  
Negative Controls ◽  
Indirect Immunofluorescent

ABSTRACTAn indirect immunofluorescent assay was developed in order to assess the serological status of 888 RT-PCR-confirmed COVID-19 patients (1,302 serum samples) and controls in Marseille, France. Incorporating an inactivated clinical SARS CoV-2 isolate as the antigen, the specificity of the assay was measured as 100% for IgA titre ≥ 1:200; 98.6% for IgM titre ≥ 1:200; and 96.3% for IgG titre ≥ 1:100 after testing a series of negative controls as well as 150 serums collected from patients with non-SARS-CoV-2 Coronavirus infection, non-Coronavirus pneumonia and infections known to elicit false-positive serology. Seroprevalence was then measured at 3% before a five-day evolution up to 47% after more than 15 days of evolution. We observed that the seroprevalence as well as the titre of specific antibodies were both significantly higher in patients with a poor clinical outcome than in patients with a favourable evolution. These data, which have to be integrated into the ongoing understanding of the immunological phase of the infection, suggest that serotherapy may not be a therapeutic option in patients with severe COVID-19 infection. The IFA assay reported here is useful for monitoring SARS-CoV-2 exposure at the individual and population levels.

Sign in / Sign up

Export Citation Format

Share Document